Belgium-based Flamingo Therapeutics BV has appointed Andrew Denker as chief medical officer to help it build a portfolio of RNA-targeted therapeutics for cancer. He will be based in Philadelphia, US. Dr Denker was previously head of early development at ElevateBio, a cell and gene therapy company. Prior to this he was an executive at Alexion Pharmaceuticals, a developer of drugs for rare diseases which is now part of AstraZeneca Plc.
Dr Denker received a bachelor degree from Princeton University and MD and PhD degrees from Thomas Jefferson University, both in the US.
Flamingo Therapeutics announced the appointment on 4 April 2023.
Copyright 2023 Evernow Publishing Ltd